Cargando…
Development and validation of a spectrophotometric assay for measuring the activity of NADH: cytochrome b5 reductase in human tumour cells.
As part of an 'enzyme-directed' approach to bioreductive drug development, we have measured the activity of NADH: cytochrome b5 reductase (B5R) in human cancer cell lines in order to assess the role of this enzyme in activating bioreductive drugs, and thus in influencing the cytotoxicity o...
Autores principales: | Barham, H. M., Inglis, R., Chinje, E. C., Stratford, I. J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075922/ https://www.ncbi.nlm.nih.gov/pubmed/8883403 |
Ejemplares similares
-
Distribution of valence electrons of the flavin cofactor in NADH-cytochrome b(5) reductase
por: Takaba, Kiyofumi, et al.
Publicado: (2017) -
Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995) -
PB2558: REFERENCE VALUES FOR METHEMOGLOBIN LEVEL AND NADH-CYTOCHROME B5 REDUCTASE ACTIVITY IN TUNISIAN POPULATION.
por: Bouatrous, Emna, et al.
Publicado: (2023) -
Familial Congenital Methemoglobinemia in Pomeranian Dogs Caused by a Missense Variant in the NADH‐Cytochrome B5 Reductase Gene
por: Shino, H., et al.
Publicado: (2018) -
NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
por: Saunders, M P, et al.
Publicado: (2000)